NEWSROOM

MEDIA CONTACTS

 

media@galderma.com

Christian Marcoux, Chief Communications Officer: +41 76 315 26 50

Sébastien Cros, Corporate Communications Director: +41 79 529 59 85 

Filter news by date

9 . 9 . 2021

Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021

6 . 28 . 2021

 

Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States

6 . 11 . 2021

 

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

5 . 19 . 2021

 

How Galderma's Environmental, Social and corporate Governance approach guides its roadmap for sustainable growth

5 . 11 . 2021

 

Galderma launches CETAPHIL® line for sensitive skin and a new DAYLONG® sun protection product in Switzerland

5 . 6 . 2021

 

New study reveals the impact of ‘hidden acne’ on quality of life

5 . 4 . 2021

 

Galderma launches new Multichannel Medical Education platform: Inaugural webinar series on the impact of mask wearing on skin diseases

4 . 28 . 2021

 

Galderma acts on workplace health and safety

4 . 21 . 2021

 

#RosaceaUnmasked by Galderma unites the rosacea community to shine light on the impact of essential COVID-19 mask-wearing this Rosacea Awareness Month

4 . 8 . 2021

 

Galderma announces publication of phase 2b trial results demonstrating the rapid and long-lasting benefits of nemolizumab in clinical trial subjects with uncontrolled atopic dermatitis

4 . 6 . 2021

 

Unveiling the new Galderma!

3 . 10 . 2021

 

Galderma online survey reveals almost two thirds of rosacea patients* are experiencing worsening of signs and symptoms related to essential COVID-19 mask wearing

3 . 4 . 2021

Press Releases  

Galderma continues global growth ambition with Sculptra® (injectable poly-L-lactic acid) re-launch in Europe